Chapter review

Fitzgerald PMHNP board review. ch10. Schizophrenia. This is drive 3 of 6. When I say Pause. Answer. wait, then I will give the answer. New section. Antipsychotic selection, EPS, NMS, and monitoring. Topic. FGA vs SGA selection. Bottom Line Summary. * **First-line treatment status**: Second-generation antipsychotics (SGAs) such as risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, and paliperidone are first-line for schizophrenia due to lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), as well as superior efficacy for negative symptoms. * **Mechanism of action differences**: First-generation antipsychotics (FGAs) act via potent D2 dopamine receptor antagonism. SGAs combine D2 dopamine antagonism with 5-HT2A serotonin antagonism or partial agonism, which mitigates EPS and addresses negative symptoms. * **Clozapine parameters**: Clozapine is a third-line agent reserved for treatment-resistant schizophrenia (failure of two prior trials), persistent suicide risk, or severe aggression. It requires an absolute neutrophil count (ANC) of 1,500/mm3 or higher to initiate (1,000/mm3 for benign ethnic neutropenia) and must be stopped if ANC falls below 1,000/mm3. * **Clozapine monitoring timeline**: ANC monitoring is required weekly for the first 6 months, every 2 weeks for months 6 through 12, and monthly thereafter. Small bowel obstruction from severe constipation is a major physical safety risk requiring a prophylactic bowel regimen. * **Tobacco smoke induction**: Tobacco smoke byproducts induce the CYP1A2 isoenzyme, significantly decreasing blood levels of clozapine and olanzapine. Quitting smoking leads to rising drug levels and potential toxicity. * **NMS clinical presentation**: Neuroleptic Malignant Syndrome (NMS) presents with muscle rigidity, hyperthermia, altered mental status, and autonomic instability. Serum creatine kinase (CK) elevates above 1,000 IU/L up to 100,000 IU/L due to severe rhabdomyolysis. * **Tardive dyskinesia timeline and assessment**: Tardive dyskinesia consists of involuntary choreoathetoid movements occurring after chronic antipsychotic exposure or within 4 weeks of oral discontinuation (8 weeks for depot). Evaluate using the Abnormal Involuntary Movement Scale (AIMS). * **Metabolic monitoring parameters**: SGAs require baseline BMI, blood pressure, fasting blood glucose or HbA1c, and lipid panel, with follow-up metabolic screening every 3 to 12 months. High-Yield Concept Breakdown: FGA vs SGA Selection, EPS, NMS, and Monitoring. First-Line Antipsychotic Selection and Receptor Dynamics. **First-line** pharmacotherapy for schizophrenia relies on second-generation antipsychotics. SGAs provide comparable control of positive symptoms (hallucinations, delusions, disorganized speech) to FGAs, but offer superior management of negative symptoms (avolition, flat affect, social withdrawal) and a significantly reduced risk of neurological motor side effects. FGAs such as haloperidol, fluphenazine, chlorpromazine, and perphenazine exert their clinical effect purely through strong D2 receptor blockade in the mesolimbic pathway. This high-potency D2 antagonism in the nigrostriatal pathway triggers acute EPS and long-term tardive dyskinesia. SGAs combine D2 dopamine receptor antagonism with 5-HT2A serotonin receptor blockade. Serotonin inhibition in the nigrostriatal tract causes downstream dopamine release, which reduces movement disorders while maintaining antipsychotic efficacy in the mesolimbic tract. **Safety alert**: SGAs carry a significant risk for metabolic syndrome. Olanzapine and clozapine produce the highest risk of weight gain, dyslipidemia, and new-onset diabetes. Quetiapine produces marked sedation and weight gain. Ziprasidone is metabolic-neutral but carries the highest risk of QTc prolongation among SGAs and must be taken with a meal of at least 500 calories for proper absorption. Aripiprazole acts as a D2 partial agonist, resulting in minimal metabolic disturbance but an increased incidence of akathisia. **Board trap**: Do not confuse local clinic prescribing habits with national examination standards. On board exams, FGAs are never first-line choices unless a patient has a documented history of excellent response and minimal side effects on an FGA in the past. Treatment-Resistant Psychosis and Clozapine Management. Clozapine is the most effective antipsychotic for severe, refractory schizophrenia. It is indicated after a patient fails at least two adequate trials of other antipsychotics, or when severe persistent suicidality or uncontrollable aggression is present. **Safety alert**: Clozapine carries a 1% to 2% risk of life-threatening agranulocytosis. Baseline ANC must be checked prior to initiation and must be at least 1,500/mm3 for the general population or at least 1,000/mm3 for individuals with documented benign ethnic neutropenia. The monitoring schedule requires weekly blood draws for 6 months, biweekly draws for the next 6 months, and monthly draws thereafter for the duration of treatment. Therapy must be interrupted if the ANC drops below 1,000/mm3. Clozapine also carries severe anticholinergic properties leading to intestinal hypomotility, severe constipation, paralytic ileus, and fatal small bowel obstruction. Clinicians must initiate a proactive bowel regimen such as polyethylene glycol (Miralax) or senna at the start of clozapine therapy. **Board trap**: Tobacco smoking induces the CYP1A2 enzyme through aromatic hydrocarbons in smoke, not through nicotine itself. Because clozapine and olanzapine are CYP1A2 substrates, smoking lowers their serum concentrations. If a patient on clozapine is hospitalized and forced to stop smoking, their clozapine level will rise rapidly, increasing the risk of seizures, severe orthostasis, and respiratory depression. Extrapyramidal Symptoms and Tardive Dyskinesia. Extrapyramidal side effects arise from D2 blockade within the nigrostriatal pathway. * **Acute Dystonia**: Sudden, painful involuntary muscle spasms of the neck (torticollis), jaw (trismus), or eyes (oculogyric crisis) occurring within hours to days of starting or escalating a high-potency FGA. Treat immediately with IV or IM benztropine or diphenhydramine. Prophylactic anticholinergics are indicated when administering IM haloperidol to antipsychotic-naive patients. * **Akathisia**: Subjective motor restlessness, pacing, and an internal feeling of wanting to jump out of one's skin. Treat by lowering the antipsychotic dose, switching to an agent with lower EPS risk, or adding a beta-blocker such as propranolol. * **Parkinsonism**: Muscle rigidity, cogwheeling, shuffling gait, bradykinesia, mask-like facies, and resting tremor emerging over days to weeks. Treat with oral benztropine or amantadine. Re-evaluate and taper anticholinergics after weeks to months to prevent chronic anticholinergic toxicity. * **Tardive Dyskinesia**: Involuntary, repetitive, choreoathetoid movements of the tongue, lips, face, trunk, or extremities (lip smacking, grimacing, tongue protrusion, rapid eye blinking) appearing after long-term antipsychotic exposure or within 4 weeks of oral withdrawal (8 weeks for depot). Assess using the Abnormal Involuntary Movement Scale (AIMS). Treatment involves discontinuing the offending agent, switching to an SGA with minimal TD risk such as clozapine or quetiapine, or initiating a vesicular monoamine transporter 2 (VMAT2) inhibitor such as valbenazine or deutetrabenazine. Neuroleptic Malignant Syndrome. **Safety alert**: Neuroleptic Malignant Syndrome is a life-threatening medical emergency with a 10% to 20% mortality rate. It can occur within 45 minutes to 65 days after starting or increasing an antipsychotic, or when rapidly switching agents. Risk factors include rapid dose escalation, parenteral administration, physical exhaustion, dehydration, and co-administration of lithium. Remember NMS using the phrase "hot, stiff, and out of it": * Severe muscle rigidity ("lead-pipe" rigidity) * Hyperthermia (fever often exceeding 102 degrees Fahrenheit) * Altered level of consciousness (confusion, delirium, coma) * Autonomic instability (tachycardia, labile blood pressure, profuse diaphoresis) Laboratory testing reveals massive elevation of serum creatine kinase (CK > 1,000 IU/L up to 100,000 IU/L) due to extensive rhabdomyolysis. Management requires immediate discontinuation of all antipsychotics and contributing agents, transfer to an intensive care unit, aggressive fluid resuscitation to prevent renal failure from myoglobinuria, and administration of dantrolene or bromocriptine. Laboratory and QTc Monitoring Guidelines. SGAs require structured laboratory monitoring due to metabolic and cardiac risks: * **Baseline assessment**: BMI, blood pressure, fasting plasma glucose or HbA1c, lipid panel, CBC, renal function, liver function tests, and baseline EKG. * **Ongoing metabolic monitoring**: Re-check weight at every visit; monitor fasting glucose and lipids at 3 months, then annually. * **QTc Prolongation**: Normal QTc is less than 450 ms in men and less than 470 ms in women. A QTc interval exceeding 500 ms or an increase of 60 ms or more from baseline warrants immediate drug discontinuation and cardiology consultation. Chapter 10 Practice Questions. Question 1. Which of the following statements is false regarding schizophrenia? A) A violent episode can be in response to a hallucination. B) The presence of a major depressive disorder episode can increase the risk of a suicide attempt. C) Suicide is attempted in up to 50% of patients with schizophrenia. D) Patients with schizophrenia are more likely to commit a homicide than a member of the general public. Pause. Answer. **Keyed Letter**: D **Why It Is Correct**: When receiving appropriate treatment, individuals with schizophrenia are no more likely to commit a homicide than members of the general public. In fact, individuals with schizophrenia are statistically far more likely to be victims of violent crime than perpetrators. **Why the Other Choices Are Wrong**: * **A**: Incorrect because violent outbursts in acute psychosis can occur directly as a reactive impulse to distressing auditory or persecutory hallucinations. * **B**: Incorrect because a co-occurring major depressive episode occurs in up to 80% of patients and significantly elevates the overall risk of suicide. * **C**: Incorrect because suicide is attempted by 20% to 50% of individuals with schizophrenia, with a lifetime completed suicide rate of approximately 5%. Question 2. According to DSM-5-TR criteria, which of the following are characteristic symptoms of schizophrenia? (Select all that apply) A) Delusions B) Hallucinations C) Compulsive behaviors D) Disorganized speech Pause. Answer. **Keyed Letter**: A, B, and D **Why It Is Correct**: DSM-5-TR Criterion A for schizophrenia requires at least two characteristic symptoms present during a one-month active phase, and at least one of those symptoms must be delusions, hallucinations, or disorganized speech. Grossly disorganized or catatonic behavior and negative symptoms comprise the remaining core Criterion A options. **Why the Other Choice Is Wrong**: * **C**: Compulsive behaviors are repetitive acts performed in response to an obsession, which defines obsessive-compulsive disorder rather than core diagnostic criteria for schizophrenia. Question 3. Laura is a 34-year-old woman diagnosed with schizophrenia 18 months ago who presents for follow-up. She mentions that she has felt "out of it" most of the day since her medication change five weeks ago. She has also gained 10 pounds (4.54 kg) since her last visit. Which medication is she most likely taking? A) Quetiapine B) Aripiprazole C) Risperidone D) Ziprasidone Pause. Answer. **Keyed Letter**: A **Why It Is Correct**: Quetiapine possesses high affinity for histamine-1 receptors, causing prominent daytime sedation (feeling "out of it") along with significant weight gain and metabolic disruption. **Why the Other Choices Are Wrong**: * **B**: Aripiprazole is a partial D2 agonist that is generally weight-neutral and activating rather than heavily sedating. * **C**: Risperidone causes weight gain and hyperprolactinemia, but quetiapine carries a distinctively higher sedating profile causing daytime sluggishness. * **D**: Ziprasidone is a weight-neutral SGA that requires administration with a 500-calorie meal for adequate bio-availability. Question 4. Indicate whether each of the following is a positive (P) or negative (N) schizophrenia symptom: 1. Hallucinations 2. Poverty of speech 3. Avoidance of eye contact 4. Disorganized behavior Pause. Answer. **Keyed Letter**: 1 is Positive (P), 2 is Negative (N), 3 is Negative (N), 4 is Positive (P) **Why It Is Correct**: Positive symptoms represent excess or distortion of normal function (hallucinations, delusions, disorganized speech, disorganized behavior). Negative symptoms represent a loss or reduction of normal functioning (poverty of speech or alogia, reduced eye contact, flat affect, avolition). **Why the Other Choices Are Wrong**: * **2 and 3**: These represent behavioral deficits rather than active psychotic additions, making them negative symptoms that respond less effectively to FGAs. * **1 and 4**: These represent active additions to normal mental operation, making them positive symptoms that respond well to D2 receptor blockade. Question 5. Mrs. Engle is a 75-year-old woman with a 40-year history of type 2 diabetes mellitus who is referred for consultation regarding new-onset visual hallucinations. She describes seeing pictures of familiar scenes and people, but does not hear voices. She is aware that these images are not real, remains alert and lucid, and has no cognitive impairment or past psychiatric history. Her vision has been slowly deteriorating over the past seven years due to macular degeneration. Which of the following is the most likely explanation for this patient? A) Disorganized schizophrenia B) Early sign of Alzheimer's disease C) Charles Bonnet syndrome D) Temporal lobe epilepsy Pause. Answer. **Keyed Letter**: C **Why It Is Correct**: Charles Bonnet syndrome occurs in elderly individuals experiencing significant vision loss (such as macular degeneration or diabetic retinopathy). Patients experience complex, vivid visual hallucinations while maintaining intact cognition, full alertness, and complete insight that the visions are ungrounded in reality. **Why the Other Choices Are Wrong**: * **A**: Late-life onset of schizophrenia after age 60 is extremely rare, and schizophrenia requires core thought disorder or negative symptoms with impaired reality testing. * **B**: Alzheimer's disease presents with prominent progressive memory loss and executive dysfunction before visual hallucinations appear in moderate to severe stages. * **D**: Temporal lobe epilepsy causes brief, paroxysmal uncinate fits, olfactory hallucinations, or altered awareness rather than chronic, lucid visual visions. Question 6. A 22-year-old male diagnosed with paranoid schizophrenia has been taking haloperidol for six months. During this visit, the PMHNP observes involuntary, repetitive muscle movements and excessive eye blinking that were not documented at his last visit. What is the appropriate next course of action? A) Measure serum ALT and AST B) Measure serum creatinine C) Administer PHQ-9 questionnaire and compare to baseline value D) Administer AIMS questionnaire and compare to baseline value Pause. Answer. **Keyed Letter**: D **Why It Is Correct**: The Abnormal Involuntary Movement Scale (AIMS) is the mandatory standardized assessment tool used to screen for, quantify, and track tardive dyskinesia in patients receiving antipsychotics. **Why the Other Choices Are Wrong**: * **A**: Transaminase levels assess hepatocellular injury, which does not evaluate extrapyramidal motor signs. * **B**: Serum creatinine measures renal filtration function, which is unrelated to involuntary movement disorders. * **C**: The PHQ-9 measures depression severity rather than antipsychotic-induced motor dyskinesia. Question 7. A 22-year-old patient is newly diagnosed with schizophrenia and presents for an outpatient appointment with his parents. Which of the following does the PMHNP realize is the most critical task to complete at this visit? A) Notify the patient's school or work of the diagnosis B) Educate the patient on the importance of medication adherence C) Reassure family members of a low risk of suicide attempt D) Educate family members of possible increased risk for homicidal tendencies Pause. Answer. **Keyed Letter**: B **Why It Is Correct**: Establishing medication adherence early in the disease course is the single most critical intervention to prevent psychotic relapse, brain tissue loss from recurrent episodes, and repeated hospitalizations. **Why the Other Choices Are Wrong**: * **A**: Disclosing confidential medical diagnoses to an employer or educational institution without explicit written patient authorization violates federal HIPAA regulations. * **C**: Reassuring the family of a low suicide risk is factually incorrect and unsafe, as 20% to 50% of schizophrenia patients attempt suicide. * **D**: Stating that schizophrenia carries an inherently high homicidal risk promotes stigma, as treated patients show no higher rate of homicide than the general public. Question 8. The PMHNP would anticipate that treatment commonly employed to reduce the morbidity of schizophrenia would include all of the following EXCEPT: A) Psychodynamic psychotherapy B) Cognitive behavioral therapy C) Assertive community treatment D) Social skills training Pause. Answer. **Keyed Letter**: A **Why It Is Correct**: Psychodynamic psychotherapy focuses on unconscious conflict and regression, which lacks empirical support for treating schizophrenia and may exacerbate anxiety or psychotic disorganization. **Why the Other Choices Are Wrong**: * **B**: CBT for psychosis is an established evidence-based modality that helps patients evaluate and reframe distressing beliefs and hallucinations. * **C**: Assertive Community Treatment (ACT) provides mobile, multi-disciplinary team-based care that significantly reduces hospital readmissions and homelessness. * **D**: Social skills training provides structured behavioral practice to rebuild interpersonal, vocational, and daily living activities. Question 9. A 34-year-old male is brought to the emergency department with symptoms of muscle rigidity, hyperthermia, and altered mental status. He has been receiving fluphenazine for three weeks and initiated lithium therapy recently. Which expected laboratory finding matches this patient? A) Hemoglobin A1c greater than 8.5% B) Platelets equal to 650,000 C) Serum creatine kinase greater than 1,000 IU/L D) ALT to AST ratio greater than 5 to 1 Pause. Answer. **Keyed Letter**: C **Why It Is Correct**: Massive elevation of serum creatine kinase (CK > 1,000 IU/L up to 100,000 IU/L) reflects severe rhabdomyolysis and muscle necrosis from "lead-pipe" rigidity in Neuroleptic Malignant Syndrome. **Why the Other Choices Are Wrong**: * **A**: Elevated HbA1c indicates chronic hyperglycemia from metabolic syndrome, not acute NMS rhabdomyolysis. * **B**: Reactive thrombocytosis is not a diagnostic marker or expected feature of NMS. * **D**: Transaminase ratios evaluate hepatic pathology rather than acute skeletal muscle destruction. 💡 **Next Study Step**: Proceed to **Fitzgerald Chapter 11: Substance-Related and Addictive Disorders** to master the neurobiology of addiction, alcohol withdrawal protocols, opioid harm reduction, and the management of dual-diagnosis psychiatric comorbidities. Next. Topic. Metabolic monitoring protocol. Bottom Line Summary. * Baseline metabolic screening before starting any second-generation antipsychotic requires personal and family cardiovascular history, height, weight, **BMI**, waist circumference, blood pressure, fasting plasma glucose or HbA1c, and a fasting lipid profile. * Weight and **BMI** must be evaluated monthly for the first 3 months of treatment and then quarterly every 3 months thereafter. * Blood pressure, fasting plasma glucose or HbA1c, and fasting lipid profiles must be rechecked at 3 months after starting therapy and then monitored at least annually. * **clozapine** and **olanzapine** carry the highest risk for extreme weight gain, severe hypertriglyceridemia, insulin resistance, and new-onset diabetes mellitus. * **quetiapine**, **risperidone**, and **paliperidone** demonstrate moderate metabolic risk and require strict routine laboratory surveillance. * **aripiprazole**, **ziprasidone**, **lurasidone**, **cariprazine**, and **lumateperone** are metabolic-neutral second-generation antipsychotics that present low risk for weight gain or glucose elevation. * A weight gain exceeding 7% of baseline body weight indicates significant metabolic dysfunction and necessitates nutritional intervention or switching to a metabolic-neutral agent. High-Yield Concept Map: Metabolic Monitoring Protocol. * **What it is**: A standardized clinical screening and laboratory surveillance schedule designed to detect and manage cardiovascular and endocrine complications induced by second-generation antipsychotics. * **Why boards care**: Cardiovascular disease driven by metabolic syndrome is a leading cause of premature mortality in patients with **schizophrenia**, shortening life expectancy by up to 20 to 25 years. * **Must know criteria and timelines**: * Baseline: Obtain height, weight, **BMI**, waist circumference, blood pressure, fasting plasma glucose or HbA1c, and fasting lipid panel. * 1 month to 3 months: Measure weight and **BMI** monthly for the first 3 months. * 3 months: Recheck blood pressure, fasting plasma glucose, and fasting lipid panel. * Quarterly: Re-evaluate weight and **BMI** every 3 months. * Annually: Check waist circumference, blood pressure, fasting plasma glucose or HbA1c, and fasting lipid profile every year. * **Typical board clue**: A patient with **schizophrenia** taking **olanzapine** or **clozapine** presents with rapid weight gain, polydipsia, polyuria, or elevated fasting triglycerides at a 3-month follow-up. * **First-line approach**: Obtain baseline fasting glucose and lipid panels before prescribing any second-generation antipsychotic. Select a metabolic-neutral agent if baseline metabolic risk is high. * **When the answer changes**: * If fasting glucose exceeds 126 mg/dL or HbA1c exceeds 6.5%, initiate diabetic management or switch to a metabolic-neutral antipsychotic. * If weight increases by more than 7% from baseline, offer dietary counseling and evaluate switching to **aripiprazole** or **ziprasidone**. * **Safety alert**: Second-generation antipsychotics can trigger rapid-onset diabetic ketoacidosis (DKA) or severe hyperglycemic hyperosmolar state, even in patients without a prior diagnosis of diabetes. Clinical Signposts and Strategic Exam Rules. * **First-line**: Order baseline fasting plasma glucose, fasting lipid panel, and **BMI** prior to initiating any second-generation antipsychotic. * **Safety alert**: **clozapine** and **olanzapine** carry black box warnings and high clinical alerts for severe metabolic disruption, requiring vigilant tracking of fasting glucose and lipid parameters. * **Board trap**: Assuming normal baseline laboratory values eliminate the need for follow-up testing. The exam tests whether you recheck fasting glucose and lipid profiles at the 3-month mark regardless of normal baseline results. Spoken Protocol Teaching: Monitoring Timelines and Drug Risk Tiers. Recommended Baseline and Follow-Up Surveillance Schedule. All second-generation antipsychotics require a complete baseline assessment before treatment begins. This baseline includes personal and family cardiovascular history, height, weight, **BMI**, waist circumference, blood pressure, fasting plasma glucose, and a fasting lipid profile. Weight and **BMI** require the most frequent early monitoring, assessed monthly for the first 3 months and then every 3 months during maintenance. Blood pressure, fasting plasma glucose, and fasting lipid profiles require a repeat assessment at 3 months to catch acute metabolic changes. Waist circumference, blood pressure, fasting glucose, and lipid panels are then reassessed annually throughout ongoing therapy. Comparative Metabolic Risk Tiers Among Second-Generation Antipsychotics. Second-generation antipsychotics differ substantially in their receptor binding profiles and metabolic adverse effect burden: * High metabolic risk: **clozapine** and **olanzapine** cause the greatest weight gain, profound hypertriglyceridemia, and severe impairment of glucose tolerance due to strong H1 histamine and 5-HT2C serotonin receptor antagonism. * Moderate metabolic risk: **quetiapine**, **risperidone**, and **paliperidone** produce moderate weight gain and intermediate elevations in glucose and lipid levels. * Low metabolic risk: **aripiprazole**, **ziprasidone**, **lurasidone**, **cariprazine**, and **lumateperone** are metabolic-neutral agents that produce minimal weight change and negligible metabolic disruption, making them preferred choices for patients with pre-existing obesity or diabetes. Board-Style Practice Question Bank. Question 1. Laura is a 34-year-old woman diagnosed with **schizophrenia** 18 months ago who presents for a routine follow-up appointment. She mentions that she has felt out of it most of the day since her medication was changed 5 weeks ago. She also states that she has gained 10 pounds (4.54 kg) since her last visit. Which medication is this patient most likely taking? A. **quetiapine** B. **aripiprazole** C. **risperidone** D. **ziprasidone** Pause. **Quick Answer**: **quetiapine** is the correct option due to its high H1 receptor affinity causing marked daytime sedation and substantial metabolic weight gain. **Key Clue**: The combination of rapid weight gain and feeling out of it daytime sedation shortly after a medication change points to a high-histamine, high-metabolic SGA. **Best Answer**: A. **quetiapine** **Why It Is Correct**: **quetiapine** causes prominent daytime sedation due to potent histamine H1 receptor blockade and produces significant weight gain. While **risperidone** can also cause weight gain, **quetiapine** is uniquely recognized for causing pronounced daytime somnolence described by patients as feeling out of it. **Why the Other Choices Are Wrong**: * A. **quetiapine** is correct. * B. **aripiprazole** is a partial dopamine agonist that is metabolic-neutral and rarely causes significant weight gain or daytime sedation. * C. **risperidone** causes moderate weight gain and hyperprolactinemia, but produces less daytime sedation than **quetiapine**. * D. **ziprasidone** is a metabolic-neutral second-generation antipsychotic with a low incidence of weight gain or daytime sedation. **Test-Taking Pearl**: When an exam stem describes significant weight gain paired with heavy daytime somnolence following an SGA switch, select **quetiapine** or **olanzapine**. **Concept tested**: Second-generation antipsychotic metabolic and sedative side-effect profiles. Question 2. A 28-year-old male with **schizophrenia** is being started on **olanzapine** for acute psychotic symptoms. Prior to initiating treatment, the PMHNP orders a baseline fasting lipid panel, fasting plasma glucose, and **BMI**. According to national monitoring guidelines, at what timeframe should the fasting plasma glucose and lipid panel be rechecked? A. 2 weeks B. 1 month C. 3 months D. 12 months Pause. **Quick Answer**: Fasting plasma glucose and fasting lipids must be rechecked 3 months after initiating second-generation antipsychotic therapy. **Key Clue**: National ADA and APA guidelines mandate a 3-month laboratory recheck for glucose and lipids following SGA initiation. **Best Answer**: C. 3 months **Why It Is Correct**: National guidelines established by the American Diabetes Association and American Psychiatric Association specify that fasting plasma glucose (or HbA1c) and fasting lipid panels must be reassessed 3 months after starting a second-generation antipsychotic. Weight and **BMI** are checked monthly for 3 months, but laboratory panels are scheduled at the 3-month mark. **Why the Other Choices Are Wrong**: * A. 2 weeks is too early for routine metabolic laboratory rechecking, although acute adverse effects or EPS are monitored early. * B. 1 month is the schedule for monthly **BMI** and weight checks during the first 3 months, not the routine glucose or lipid laboratory panel. * C. 3 months is the correct interval for laboratory glucose and lipid reassessment. * D. 12 months is the annual maintenance schedule after the initial 3-month laboratory recheck has been completed. **Test-Taking Pearl**: Memorize the 3-month rule for SGA laboratory monitoring: glucose, lipids, and blood pressure all require a 3-month recheck before transitioning to annual testing. **Concept tested**: Second-generation antipsychotic metabolic monitoring protocol timelines. Active Recall Checkpoints. * What six specific laboratory and physical parameters must be documented at baseline before starting an SGA? * How frequently must **BMI** and weight be measured during the first 3 months of SGA therapy? * At what specific post-initiation timeframe must fasting plasma glucose and lipid panels be re-evaluated? * Which two second-generation antipsychotics carry the highest risk for severe weight gain, dyslipidemia, and new-onset diabetes mellitus? * What percentage of body weight gain from baseline is considered a critical threshold for clinical intervention? Next Study Step. Review **Clozapine and Specialized Monitoring**, focusing on absolute neutrophil count (ANC) thresholds, agranulocytosis risk management, and mandatory monitoring intervals. This closes the gap between general SGA metabolic surveillance and high-risk hematologic safety parameters tested on boards. Next. Topic. EPS and NMS management. Bottom Line Summary. * **Neuroleptic malignant syndrome** is a life-threatening emergency with a mortality rate of 10% to 20%, characterized by hyperthermia, muscle rigidity, autonomic instability, altered mental status, and a serum **creatine kinase** level exceeding 1000 IU/L up to 100000 IU/L. * Acute **dystonia** presents as sudden muscle spasms like torticollis within hours to days of starting antipsychotics, requiring IM or IV **benztropine** or **diphenhydramine** for severe episodes. * **Akathisia** presents as motor restlessness and a subjective urge to move; **propranolol** is the **First-line** agent. * **Parkinsonism** features bradykinesia, rigidity, and shuffling gait; it is managed by lowering the dose or adding **benztropine** or **amantadine**. * **Tardive dyskinesia** involves involuntary facial or lingual movements occurring during treatment, within 4 weeks of stopping oral agents, or within 8 weeks of stopping depot injections; it is monitored using the **AIMS** scale and treated with **VMAT2** inhibitors like **valbenazine** or **deutetrabenazine**. * **Clozapine** and **quetiapine** carry the lowest risk of **tardive dyskinesia**, making them preferred SGAs when motor complications arise. EPS Management and Prevention. Assessment and Risk Timelines. * Evaluate patients for extrapyramidal symptoms weekly until the medication dose has been stable for at least 2 weeks. * Early extrapyramidal symptoms serve as critical warning signs for the future development of **tardive dyskinesia**. Extrapyramidal Symptom Types and Clinical Features. * **Dystonia**: Acute, rapid onset of painful muscle contractions, such as torticollis or oculogyric crisis. * **Akathisia**: Subjective feeling of internal restlessness or feeling like wanting to jump out of one's skin, accompanied by pacing or foot tapping. * **Parkinsonism**: Stiff, rigid muscles, bradykinesia, shuffling gait, masked facies, resting tremor, and cogwheel rigidity. Treatment Strategies for EPS. * **First-line** for **akathisia**: Centrally acting beta blockers, specifically **propranolol**. * **First-line** for **parkinsonism**: Anticholinergic medications such as **benztropine** or dopamine agonists like **amantadine**. * Treatment for **dystonia**: Mild symptoms respond to oral **benztropine**. Severely disturbing acute dystonia requires IM or IV **benztropine** or **diphenhydramine**. * **Safety alert**: Prophylactic anticholinergic use is generally not recommended, with one major exception: initiating parenteral **haloperidol** for acute agitation, particularly in antipsychotic naive patients. * **Board trap**: Keeping patients on long term anticholinergics like **benztropine** can cause severe anticholinergic toxicity and cognitive decline. Anticholinergic drugs should be maintained at the lowest effective dose for the shortest necessary duration and reassessed for discontinuation after weeks to months. Tardive Dyskinesia Management. Clinical Presentation and Timing. * Involuntary, repetitive muscle movements including facial grimacing, lip smacking, tongue protrusion, rapid eye blinking, and choreiform limb movements. * Onset occurs during antipsychotic therapy, within 4 weeks of discontinuing an oral antipsychotic, or within 8 weeks of discontinuing a depot long-acting injectable. Prevention, Screening, and Intervention. * Screen all patients receiving antipsychotics using the **AIMS** (Abnormal Involuntary Movement Scale) tool at baseline and periodically. * **First-line** intervention for early detection: Reduce the dose or discontinue the offending agent, or switch from an FGA to an SGA with low EPS liability, specifically **clozapine** or **quetiapine**. * Treatment for moderate to severe or disabling **tardive dyskinesia**: **VMAT2** inhibitors, such as **valbenazine** or **deutetrabenazine**. Secondary options include **benzodiazepines** or **botulinum toxin** injections. Neuroleptic Malignant Syndrome Management. Clinical Presentation and Lab Findings. * **Safety alert**: **Neuroleptic malignant syndrome** is a medical emergency with a 10% to 20% mortality rate. * Clinical presentation is remembered as hot, stiff, and out of it: severe hyperthermia, extreme generalized muscle rigidity, altered level of consciousness, and autonomic dysfunction (tachycardia, labile blood pressure, diaphoresis). * Characteristic laboratory finding: Markedly elevated serum **creatine kinase** (**CPK**), ranging from 1000 IU/L to 100000 IU/L, reflecting intense muscle breakdown. Elevated **CPK** directly correlates with the degree of muscle rigidity and creates a high risk for myoglobinuria and acute renal failure. Timing, Triggering Agents, and Risk Factors. * Can develop as early as 45 minutes or as late as 65 days after antipsychotic initiation or dose adjustment. * **Board trap**: Assuming **neuroleptic malignant syndrome** only occurs with high-potency FGAs like **haloperidol**. While the incidence is highest with FGAs (up to 3%), it can also occur with SGAs, antiemetic dopamine antagonists (such as **metoclopramide**, **promethazine**, **prochlorperazine**, **droperidol**), or abrupt withdrawal of dopamine agonists. * Contributing risk factors: Rapid dose escalation, parenteral administration, switching antipsychotics, and concurrent use of **lithium**, anticholinergic, or serotonergic agents. Emergency Management Protocol. * **First-line** action: Immediately discontinue the offending antipsychotic and all potential contributing psychotropic agents. * Medical stabilization: Transfer the patient immediately to an intensive care or tertiary care facility for aggressive supportive care, including IV hydration to preserve renal function and active cooling measures. * Pharmacologic treatment in severe cases: Administer the direct acting muscle relaxant **dantrolene** or the dopamine agonist **bromocriptine**. Fitzgerald Sample Test Questions. Question 6. A 22-year-old male diagnosed with paranoid **schizophrenia** has been taking **haloperidol** for the past six months. During this visit, the PMHNP acknowledges involuntary, repetitive muscle movements and excessive eye blinking that were not documented at his last visit. The appropriate next course of action will be to: A) measure serum ALT AST B) measure serum creatinine C) administer PHQ-9 questionnaire and compare it to baseline value D) administer **AIMS** questionnaire and compare it to baseline value Pause. Answer. Keyed Letter: D Why Correct: The patient exhibits classic signs of **tardive dyskinesia**, including involuntary repetitive muscle movements and eye blinking. The **AIMS** (Abnormal Involuntary Movement Scale) is the standardized clinical tool used to quantify the severity of involuntary movements and compare current findings against baseline. Why Each Distractor Fails: * Choice A is incorrect because serum transaminases (ALT/AST) evaluate hepatic function, which is unrelated to identifying or scoring movement disorders. * Choice B is incorrect because serum creatinine evaluates renal clearance, which does not assist in evaluating motor side effects. * Choice C is incorrect because the PHQ-9 measures depressive symptoms, not extrapyramidal or dyskinetic movement disorders. Question 9. A 34-year-old male is brought into the ED with symptoms of muscle rigidity, hyperthermia, and altered mental status. He has been receiving **fluphenazine** for the past three weeks and initiated **lithium** therapy only recently. An expected finding from this patient is: A) an A1C greater than 8.5% B) platelets equal to 650,000 C) serum **creatine kinase** greater than 1000 IU per liter D) ALT AST ratio greater than 5 to 1 Pause. Answer. Keyed Letter: C Why Correct: The patient presents with the classic triad of **neuroleptic malignant syndrome**: severe hyperthermia, muscle rigidity, and altered sensorium ("hot, stiff, and out of it") after receiving an FGA (**fluphenazine**) combined with **lithium**. Massive elevation of serum **creatine kinase** (greater than 1000 IU/L up to 100000 IU/L) confirms muscle necrosis and correlates with the severity of rigidity. Why Each Distractor Fails: * Choice A is incorrect because an elevated HbA1c reflects chronic glycemic control or metabolic syndrome, not acute rhabdomyolysis from **neuroleptic malignant syndrome**. * Choice B is incorrect because elevated platelet count (thrombocytosis) is an acute phase reactant or hematologic finding, not the defining diagnostic lab for **neuroleptic malignant syndrome**. * Choice D is incorrect because an elevated liver enzyme ratio reflects hepatotoxicity or alcohol-induced liver disease rather than acute muscle destruction. Next. End of this drive.